Therefore, the FDA has approved the use of the combination of pertuzumab and trastuzumab with chemotherapy in metastatic breast cancer and early HER2-overexpressing breast cancer in the neoadjuvant setting. This evidence concerns the gene ERBB2 and breast cancer.